vs
Side-by-side financial comparison of Hippo Holdings Inc. (HIPO) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
Hippo Holdings Inc. is the larger business by last-quarter revenue ($120.4M vs $86.8M, roughly 1.4× IOVANCE BIOTHERAPEUTICS, INC.). On growth, Hippo Holdings Inc. posted the faster year-over-year revenue change (18.2% vs 17.7%). Hippo Holdings Inc. produced more free cash flow last quarter ($9.1M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 18.9%).
Hippo Valley Estate is a sugar estate found near the town of Chiredzi in Chiredzi District of southeastern Zimbabwe, on the Runde River near the border with Mozambique.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
HIPO vs IOVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $120.4M | $86.8M |
| Net Profit | $6.0M | — |
| Gross Margin | — | 67.4% |
| Operating Margin | 5.6% | -84.7% |
| Net Margin | 5.0% | — |
| Revenue YoY | 18.2% | 17.7% |
| Net Profit YoY | -86.4% | — |
| EPS (diluted) | $0.31 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $120.4M | $86.8M | ||
| Q3 25 | $120.6M | $67.5M | ||
| Q2 25 | $117.3M | $60.0M | ||
| Q1 25 | $110.3M | $49.3M | ||
| Q4 24 | $101.9M | $73.7M | ||
| Q3 24 | $95.5M | $58.6M | ||
| Q2 24 | $89.6M | $31.1M | ||
| Q1 24 | $85.1M | $715.0K |
| Q4 25 | $6.0M | — | ||
| Q3 25 | $98.1M | $-91.3M | ||
| Q2 25 | $1.3M | $-111.7M | ||
| Q1 25 | $-47.7M | $-116.2M | ||
| Q4 24 | $44.2M | — | ||
| Q3 24 | $-8.5M | $-83.5M | ||
| Q2 24 | $-40.5M | $-97.1M | ||
| Q1 24 | $-35.7M | $-113.0M |
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% | ||
| Q1 24 | — | — |
| Q4 25 | 5.6% | -84.7% | ||
| Q3 25 | 81.3% | -140.7% | ||
| Q2 25 | 3.4% | -189.8% | ||
| Q1 25 | -41.3% | -245.8% | ||
| Q4 24 | 46.3% | -117.5% | ||
| Q3 24 | -5.4% | -152.1% | ||
| Q2 24 | -40.7% | -327.6% | ||
| Q1 24 | -38.7% | -16464.6% |
| Q4 25 | 5.0% | — | ||
| Q3 25 | 81.3% | -135.3% | ||
| Q2 25 | 1.1% | -186.2% | ||
| Q1 25 | -43.2% | -235.5% | ||
| Q4 24 | 43.4% | — | ||
| Q3 24 | -8.9% | -142.7% | ||
| Q2 24 | -45.2% | -312.2% | ||
| Q1 24 | -42.0% | -15800.8% |
| Q4 25 | $0.31 | — | ||
| Q3 25 | $3.77 | — | ||
| Q2 25 | $0.05 | $-0.33 | ||
| Q1 25 | $-1.91 | $-0.36 | ||
| Q4 24 | $1.81 | $-0.24 | ||
| Q3 24 | $-0.34 | $-0.28 | ||
| Q2 24 | $-1.64 | $-0.34 | ||
| Q1 24 | $-1.47 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $218.3M | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $436.1M | $698.6M |
| Total Assets | $1.9B | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $218.3M | $297.0M | ||
| Q3 25 | $247.7M | $300.8M | ||
| Q2 25 | $198.9M | $301.2M | ||
| Q1 25 | $140.9M | $359.7M | ||
| Q4 24 | $197.6M | $323.8M | ||
| Q3 24 | $191.2M | $397.5M | ||
| Q2 24 | $175.9M | $412.5M | ||
| Q1 24 | $223.4M | $356.2M |
| Q4 25 | $436.1M | $698.6M | ||
| Q3 25 | $421.5M | $702.3M | ||
| Q2 25 | $332.5M | $698.5M | ||
| Q1 25 | $322.8M | $767.9M | ||
| Q4 24 | $362.1M | $710.4M | ||
| Q3 24 | $326.4M | $773.5M | ||
| Q2 24 | $322.6M | $768.5M | ||
| Q1 24 | $351.2M | $680.0M |
| Q4 25 | $1.9B | $913.2M | ||
| Q3 25 | $1.9B | $904.9M | ||
| Q2 25 | $1.7B | $907.4M | ||
| Q1 25 | $1.5B | $966.7M | ||
| Q4 24 | $1.5B | $910.4M | ||
| Q3 24 | $1.5B | $991.1M | ||
| Q2 24 | $1.5B | $964.3M | ||
| Q1 24 | $1.5B | $869.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.2M | $-52.6M |
| Free Cash FlowOCF − Capex | $9.1M | $-61.9M |
| FCF MarginFCF / Revenue | 7.6% | -71.3% |
| Capex IntensityCapex / Revenue | 0.1% | 10.7% |
| Cash ConversionOCF / Net Profit | 1.53× | — |
| TTM Free Cash FlowTrailing 4 quarters | $14.8M | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.2M | $-52.6M | ||
| Q3 25 | $16.9M | $-78.7M | ||
| Q2 25 | $24.7M | $-67.4M | ||
| Q1 25 | $-35.6M | $-103.7M | ||
| Q4 24 | $47.5M | $-73.3M | ||
| Q3 24 | $46.8M | $-59.0M | ||
| Q2 24 | $-10.6M | $-98.4M | ||
| Q1 24 | $17.7M | $-122.3M |
| Q4 25 | $9.1M | $-61.9M | ||
| Q3 25 | $16.8M | $-89.5M | ||
| Q2 25 | $24.6M | $-74.9M | ||
| Q1 25 | $-35.7M | $-109.9M | ||
| Q4 24 | $47.2M | $-77.5M | ||
| Q3 24 | — | $-61.3M | ||
| Q2 24 | $-10.7M | $-98.9M | ||
| Q1 24 | $17.6M | $-126.5M |
| Q4 25 | 7.6% | -71.3% | ||
| Q3 25 | 13.9% | -132.7% | ||
| Q2 25 | 21.0% | -124.9% | ||
| Q1 25 | -32.4% | -222.8% | ||
| Q4 24 | 46.3% | -105.1% | ||
| Q3 24 | — | -104.6% | ||
| Q2 24 | -11.9% | -317.9% | ||
| Q1 24 | 20.7% | -17685.3% |
| Q4 25 | 0.1% | 10.7% | ||
| Q3 25 | 0.1% | 16.1% | ||
| Q2 25 | 0.1% | 12.4% | ||
| Q1 25 | 0.1% | 12.6% | ||
| Q4 24 | 0.3% | 5.7% | ||
| Q3 24 | 0.0% | 3.9% | ||
| Q2 24 | 0.1% | 1.4% | ||
| Q1 24 | 0.1% | 583.4% |
| Q4 25 | 1.53× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | 19.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.07× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HIPO
Segment breakdown not available.
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
